Private Equity Prescribes a Delisting for Recordati
Key takeaways
- Tell us how you invest and we ll show you why it s our #1 pick.
- The bid, formalized this Friday, settles months of speculation that began when CVC first lobbed a nonbinding expression of interest to Recordati s board in March.
- The cash offer represents a 12.9% premium over Recordati s share price on March 25, the final trading session before CVC’s initial overtures were made public.
Private Equity Prescribes a Delisting for Recordati Mark Nichols Fri, May 22, 2026 at 10:18 PM GMT+7 4 min read NVDA CVC.AS RCDTF RICFY Private Equity Prescribes a Delisting for Recordati - Moby THE GIST Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we ll show you why it s our #1 pick. Tap here.
A heavy-hitting buyout consortium led by private equity titan CVC Capital Partners and Belgium’s Groupe Bruxelles Lambert (GBL) has launched a €10.73 billion (about $12.47 billion) cash bid to take Italian pharmaceutical group Recordati private.
The voluntary tender offer aims to fully delist the 100-year-old company from Euronext Milan, allowing private equity players to pursue highly profitable rare-disease portfolios and dealmaking pipelines away from the short-term glare and volatility of public equity markets.